IADR Abstract Archives
Omega-3 effect on osteoarthritis symptoms of synovial joints. Review-Meta Analysis.
Objectives: To evaluate evidence, establish effectiveness and determine methodological quality of randomized clinical trials (RCTs) on the effect of omega-3 long chain polyunsaturated fatty acid (PUFA ω-3) on the painful symptomatology of osteoarthritis (OA) in synovial joints.
Methods: Electronic and manual search of articles (2004-2019) was performed. Using pain as the main outcome and rigidity/function and swelling as secondary outcomes, based on PRISMA criteria, CONSORT reporting quality and Cochrane/RoB-2 risk of bias assessment. Data were processed statistically (RevMan v.5.2).
Results: 409 studies were identified. Seven RCTs were included for qualitative assessment and six for meta-analysis (n=454 patients with OA; 234 intervention/intake ω-3 and 220 control, media=57.8 years, range 28-80 years, 68% women). Pain in the intervention group presented significantly favorable results versus control, expressed as mean difference =22.89, at 95% (CI=between 3.37-42.42; p=0.02; I2=98%) in 4 studies however, 2 RCTs were atypical. The RCTs showed high clinical and methodological variability expressed as a lack of homogeneity in the combined effect of the studies. The effective anti-inflammatory dose was not established. The most frequent adverse effects were gastrointestinal without affecting the intervention. For rigidity, function and inflammation the number of studies was low (n=2).
Conclusions: Omega-3 had significant results in pain reduction. However, the limited number of studies, the diversity of doses, sources, intervention length, baseline characteristics of the patients, asymmetry in reporting bias, along with the excessive heterogeneity of the studies, determined low quality evidence that did not allow us to offer a clinical guide that includes ω-3 for the management of pain in patients with synovial joints affected by OA.
Methods: Electronic and manual search of articles (2004-2019) was performed. Using pain as the main outcome and rigidity/function and swelling as secondary outcomes, based on PRISMA criteria, CONSORT reporting quality and Cochrane/RoB-2 risk of bias assessment. Data were processed statistically (RevMan v.5.2).
Results: 409 studies were identified. Seven RCTs were included for qualitative assessment and six for meta-analysis (n=454 patients with OA; 234 intervention/intake ω-3 and 220 control, media=57.8 years, range 28-80 years, 68% women). Pain in the intervention group presented significantly favorable results versus control, expressed as mean difference =22.89, at 95% (CI=between 3.37-42.42; p=0.02; I2=98%) in 4 studies however, 2 RCTs were atypical. The RCTs showed high clinical and methodological variability expressed as a lack of homogeneity in the combined effect of the studies. The effective anti-inflammatory dose was not established. The most frequent adverse effects were gastrointestinal without affecting the intervention. For rigidity, function and inflammation the number of studies was low (n=2).
Conclusions: Omega-3 had significant results in pain reduction. However, the limited number of studies, the diversity of doses, sources, intervention length, baseline characteristics of the patients, asymmetry in reporting bias, along with the excessive heterogeneity of the studies, determined low quality evidence that did not allow us to offer a clinical guide that includes ω-3 for the management of pain in patients with synovial joints affected by OA.
3460365_File000000.jpg
3460365_File000001.jpg
3460365_File000002.jpg